Safety of ximelagatran

JAMA. 2005 Jun 15;293(23):2859; author reply 2859-60. doi: 10.1001/jama.293.23.2859-a.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anticoagulants / adverse effects*
  • Azetidines / adverse effects*
  • Benzylamines
  • Humans
  • Prodrugs / adverse effects*
  • Product Surveillance, Postmarketing
  • Thrombosis / prevention & control

Substances

  • Anticoagulants
  • Azetidines
  • Benzylamines
  • Prodrugs
  • ximelagatran